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Abstract: Diagnostic testing for the antibody Bm14 is used to assess the prevalence of bancroftian and
brugian filariasis in endemic populations. Using dried blood spots (DBS) collected on filter paper is
ideal in resource-poor settings, but concerns have been raised about the performance of DBS samples
compared to plasma or serum. In addition, two versions of the test have been used: the Bm14 CELISA
(Cellabs Pty Ltd., Manly, Australia) or an in-house CDC version. Due to recent improvements in
the CELISA, it is timely to validate the latest versions of the Bm14 ELISA for both plasma and DBS,
especially in settings of residual infection with low antibody levels. We tested plasma and DBS
samples taken simultaneously from 92 people in Myanmar, of whom 37 (40.2%) were positive in a
rapid antigen test. Comparison of results from plasma and DBS samples demonstrated no significant
difference in positive proportions using both the CELISA (46.7% and 44.6%) and CDC ELISA (50.0%
and 47.8%). Quantitative antibody unit results from each sample type were also highly correlated,
with coefficients >0.87. The results of this study demonstrate that DBS samples are a valid collection
strategy and give equivalent results to plasma for Bm14 antibody ELISA testing by either test type.
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1. Introduction
Screening assays used in The Global Program to Eliminate Lymphatic Filariasis (GPELF) are
frequently performed in low resource settings where samples may be exposed to temperature changes
during collection, storage and transport. Diagnostic tests that can utilise dried blood spots (DBS)
collected on filter paper which do not require immediate cold storage have many advantages over
plasma samples in rural communities where lymphatic filariasis (LF) occurs.
The parasite antibody Bm14 diagnostic ELISA is among the techniques used to identify
bancroftian- and brugian-associated lymphatic filariasis (LF) [1–5] and is used alongside antigen
detection tests to monitor and evaluate endemicity in populations [2,6,7]. However, concerns over
the specificity and predictive values of the Bm14 ELISA have raised questions about its accuracy
in detecting residual endemicity or resurgence [8,9]. Of the three species detected by the Bm14
antibody test, Wuchereria bancrofti and Brugia malayi contribute 90% and 9% of LF disease burden
worldwide [10–12].
The Bm14 ELISA, commercially produced as the CELISA (Cellabs Pty Ltd., Manly, Australia),
incorporates positive and negative control samples to check plate to plate consistency [13]. The kit
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recommends using an optical density cut-off value for defining a positive result (0.4) [13], although
some studies use a lower cut-off of 0.25 [10]. The CDC Bm14 in-house version of the assay recommends
use of a standard curve to generate antibody units, with sample antibody values greater or equal to
the cut-off being considered positive [14]. For comparability in the current study, we used standard
curves generated from the same positive serum for both CELISA and CDC versions. Both versions of
the Bm14 ELISA recommend the application of either plasma or eluted DBS for antibody detection.
While there is not a true gold standard for LF positivity, previous studies have found that the
Bm14 test with plasma or serum has high sensitivity compared to microfilaria microscopy, recorded at
98% for samples from people with W. bancrofti and 91% for Brugia malayi filariasis [10]. Gass et al. [9]
found similar high specificity of 95% for plasma in anticoagulant ethylenediaminetetraacetic acid
(EDTA). However, CELISA DBS sensitivity can range from 50.0% to 92.3% when compared with
immunochromatographic testing and PCR testing, with consistently high negative predictive values
(NPV) of >96.6% [10].
While the dried blood spot method would be an inexpensive and convenient alternative to plasma
samples, Joseph and colleagues [8] have reported that specificity of DBS when using the CELISA
may be as low as 77%, with a positive predictive value (PPV) of 60% when compared to plasma
application. Knowledge gaps in the literature and the release of an improved CELISA kit by Cellabs
require additional evaluation and comparison of these methods.
This study investigates whether results obtained using DBS are valid and comparable to results
obtained using plasma with the CELISA and the CDC ELISA. These results will provide confidence in
and promote appropriate application of the Bm14 ELISA for whichever collection method is available.
2. Materials and Methods
2.1. Study Population
Amarapura Township within the Mandalay Region of Central Myanmar was selected as a study
site, as it was known from sentinel site records to have a high prevalence of LF infection. All young
people aged 10–21 years were invited to participate in a cross-sectional study. Ethical approval for the
study was given by the Myanmar Ministry of Health and Sports and James Cook University Research
Human Ethics Committee, approval number H5261.
Individuals were screened for LF infection using the BinaxNOW® filariasis immunochromatographic
test (ICT) card (Alere International Limited, Galway, Ireland). Young adults aged 18–21 years gave
written consent to participate, while parents or guardians gave written consent for participants
aged 10–17 years. An equal number of positive and negative participants were invited for a follow-up
visit; however, some chose not to attend, resulting in a final collection of 37 ICT positives and 55 ICT
negatives out of 92 total participants. The study sampling occurred shortly before the filariasis mass
drug administration was offered in this township. Follow-up visits were done after the mass drug
administration to ensure that positive participants took deworming drugs.
2.2. Preparation of Plasma and Blood Filter Paper Samples
Blood samples were collected by technical staff from the Myanmar Ministry of Health and
Sports. A 10 mL sample of venous blood was collected from all participants and stored in cooled
EDTA anticoagulant vacutainers (BD biosciences, Becton, Dickinson and Company, North Ryde, NSW,
Australia). An amount of 10 µL of collected blood was transferred using a micropipette to each of the
six protrusions of a filter paper disc (TropBio filter papers) and left to dry completely before storage in
individual plastic bags. Remaining whole blood was kept on crushed ice and delivered to the Public
Health Laboratory in Mandalay within four hours of collection. Plasma was separated from whole
blood by centrifugation at 3000× g for 15 min and aliquoted into 2 mL tubes. Plasma samples were
stored at −20 ◦C at the laboratory in Mandalay until transported to Yangon on dry ice and stored at
−80 ◦C by the Department of Medical Research (DMR). One vial of each plasma sample was thawed,
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aliquoted and refrozen for transport to James Cook University in Cairns, Australia, where it was stored
at −80 ◦C. Filter papers were sealed in plastic containers and kept in either 4 ◦C refrigeration or hand
luggage during direct transport to Cairns, where they were stored at −80 ◦C.
2.3. Preparation of Eluates from DBS
DBS eluates were prepared for the application of the commercially available Bm14 kit
(CELISA) [13] and the LF Bm14 CDC TMB-ELISA [14], using respective protocols. Sample diluent
was prepared according to the instructions, with individual 495 µL and 245 µL sample diluent
aliquots transferred into separate serum tubes for CELISA and CDC ELISA testing respectively,
using a micropipette. Single blood-soaked filter paper protrusions were transferred to two separate
serum tubes, one containing 495 µL of sample diluent to create 1:100 dilutions intended for CELISA
application, and another containing 245 µL sample diluent to create a 1:50 dilution intended for CDC
ELISA application. Each protrusion soaks exactly 10 µL of blood, with half of this volume estimated to
be plasma and the remaining 5 µL containing all other blood products. Therefore, it is assumed that
the 5 µL of plasma from each DBS added to 495 µL and 245 µL aliquots creates dilutions of 1:100 and
1:50 respectively. All samples were vortexed to ensure complete saturation of each disc and left to
elute overnight at 4 ◦C before being warmed to room temperature (RT) of between 20 ◦C and 25 ◦C
and vortexed again prior to testing.
2.4. Bm14 Filariasis Cellabs Enzyme Linked Immunosorbent Assay
Primary sample incubation was at 37 ◦C for 1 h before emptying and flooding wells with washing
buffer three times, followed by a final emptying and upside down tapping of each plate to ensure
wells were free of large droplets. Secondary IgG4 conjugates were added and incubated for 45 min
at 37 ◦C, before washing again and applying a final 15-min incubation with tetramethylbenzidine
(TMB) substrate without light exposure. Plates were prepared for optical density reading through the
addition of 50 µL of stopping solution per well.
2.5. Bm14 Filariasis CDC’s Enzyme Linked Immunosorbent Assay
Antigen sensitising buffer (ASB) was created at 0.1 M using NaHCO3 and dH2O with a pH of
9.6 using NaOH. Working antigen solution (Atlanta, CDC) was prepared at 2 µg/mL using ASB.
The binding of antigens to each well of Immulon 4HB plates (Thermofisher, Loughborough, UK)
was achieved by adding 50 µL of 1:50 antigen solution to each well of a 96-well microplate before
incubating at 4 ◦C overnight for at least 12 h. Working antigen solution was physically removed before
the addition of 100 µL of PBS + 0.3% Tween (Life Technologies, Mulgrave, VIC, Australia), pH 7.2,
to each well and incubated at 4 ◦C for 1 h.
Blanks were created by adding 50 µL of PBS with 0.05% Tween to intended blank wells. Dilutions
of plasma or DBS eluates were added at 50 µL to each experimental well before incubating at room
temperature on a rocker platform for 2 h. Washing steps between incubations were performed in an
identical fashion to the CELISA, referred to earlier. Following the addition of horseradish peroxidase
conjugated anti-human IgG4 (mouse) (Life Technologies), made to a 1:500 dilution with PBS with
0.05% Tween, at 50 µL to each plate well, the plate was incubated at room temperature for 45 min.
TMB substrate was added at 50 µL to each well and incubated at room temperature in the dark for
5 min before adding 50 µL of 1 M HCL.
2.6. Statistical Analysis
Optical density readings of each sample were measured at a dual wavelength of 450 nm/650 nm
with a VersaMax™ ELISA microplate reader (Molecular Devices, Sunnyvale, CA, USA) using SoftMax
Pro Software Version 6.4.1 (Molecular Devices, Sunnyvale, CA, USA) with background absorbance of
sample diluent subtracted.A moderately-positive sample collected from an endemic area of Papua
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New Guinea was used as a positive control, while negative controls were taken from Australian
lab workers.
A standard curve was constructed using a single highly-positive sample from Papua New
Guinea which was defined by an arbitrary high value of 1000 antibody units with subsequent 2-fold
dilutions. A single cut-off point of >125 units was used to determine positive readings based on
previous literature [5,9]. It should be noted that an optical density cut-off value of 0.4 is normally
recommended by the CELISA manual. Relative sensitivity, specificity, positive predictive values (PPV),
and negative predictive values (NPV), as well as paired t-tests, odds ratios, McNemar chi-square tests
and correlations were performed using the IBM statistical software SPSS Version 23.0. Confidence
intervals (CI) were reported at 95%.
3. Results
During October 2014, 377 young people residing in Amarapura Township were screened by ICT.
Positive cases were age and gender matched to negative cases and 112 young people were invited to
participate in a longitudinal study including provision of a blood sample. Not all participants returned
for participation, leaving a final sample of 37 (40.2%) positive and 55 (59.8%) negative samples that
were included in this study (Table 1).
Table 1. Positive proportions and chi-square results obtained when using the CELISA with plasma as
a standard.
Standard NPositive
% Positive (95%
Confidence
Interval (CI))
Comparative
Test
N
Positive
% Positive
(95% CI)
McNemar
Chi sq P Value
CELISA
Plasma
1:100
43 47 (37–57)
CELISA Dried
blood spot
(DBS) 1:100
41 45 (35–55) 0.5 0.7
- - - CDC Plasma1:50 46 50 (40–60) 1.3 0.5
- - - CDC DBS 1:50 44 48 (38–58) 0.2 0.9
3.1. Categorical Analysis and Comparisons of Plasma and DBS Using Cellabs and CDC ELISA Assays
Holding all CELISA plasma samples tested at a 1:100 dilution as a standard, we compared how
DBS application affects the proportion of positive results when using the CELISA at an identical
dilution. We found no significant difference in positive proportions between plasma (47%) and DBS
(45%) samples (Table 1).
The CELISA standard was also compared to the CDC version of the Bm14 ELISA to assess any
similarity in positive proportions when using plasma or DBS at the CDC recommended 1:50 dilution.
The proportions of samples classed as positive were not significantly different between the CELISA
standard (47%) and CDC ELISA with plasma (50%) or DBS (48%), respectively (Table 1). These three
comparisons suggest that high similarity in positive results is found between the CELISA and the CDC
ELISA using either plasma or DBS.
To establish how the CDC ELISA is affected by the application method, plasma and DBS samples
were compared using the 1:50 dilution. Positive proportions of 50% when using plasma, and 48%
when using DBS were not significantly different (Table 2). This confirms that the CDC ELISA will yield
similar results regardless of the sample application method.
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Table 2. Positives proportions and chi-square results obtained when comparing plasma and DBS with
the CDC ELISA.
Standard NPositive
% Positive
(95% CI)
Comparative
Test
N
Positive
% Positive
(95% CI)
McNemar
Chi sq P Value
CDC Plasma
1:50 46 50 (40–60)
CDC
DBS
1:50
44 48 (38–58) 1.0 0.6
3.2. Comparing the Plasma and DBS for CELISA and CDC ELISA Samples
To determine how application of plasma and filter paper affects CELISA agreement, relative
sensitivity, specificity, PPV and NPV were calculated. When DBS was compared to plasma at a 1:100
dilution using the CELISA, results were high overall at 88.4% sensitivity, 93.9% specificity, 92.7% PPV,
and 90.2% NPV (Table 3). These results suggest that the CELISA yields reliable agreement between
plasma and DBS samples.
Table 3. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and
odds ratio statistics comparisons of plasma and DBS application using the CELISA and CDC ELISA.
Standard ComparativeTest
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
Odds Ratio
(95% CI) P Value
CELISA
Plasma
1:100
CELISA DBS
1:100
88.4%
(74.9–96.1)
93.9%
(83.1–98.7)
92.7%
(80.8–95.5)
90.2%
(80.1–95.5)
116.5
(26.15–519.4) <0.0001
- CDC Plasma1:50
95.4%
(84.2–99.4)
89.8%
(77.8–96.6)
89.1%
(78.1–95.0
95.7%
(85.0–98.8)
180.4
(33.2–981.7) <0.0001
- CDC DBS1:50
95.4%
(84.2–99.4)
93.9%
(83.1–98.7)
93.2%
(82.0–97.6)
95.8%
(85.6–98.9)
314.3
(50.0–1975.4) <0.0001
Performance of the CDC ELISA using plasma and DBS at a 1:50 dilution was also compared to
the CELISA 1:100 plasma standard. Relative sensitivity was high at 95.4% for both CDC plasma and
DBS samples, with specificity found at 89.8% and 93.9% respectively (Table 3). Predictive values were
also high for both CDC plasma and DBS samples compared to CELISA plasma, yielding 89.1% and
93.2% respectively for PPV, and 95.7% and 95.8% respectively for NPV (Table 3). Therefore, there is
good agreement between the CDC ELISA using plasma and DBS when compared to results yielded by
the CELISA using plasma.
Again, we compared plasma and DBS using the CDC ELISA at the recommended dilution of
1:50, to determine how test performance and relative predictive values are affected. Sensitivity and
specificity were 97.7% and 93.8% respectively, while PPV and NPV were 93.5% and 97.8% respectively
(Table 4). These results suggest that the CDC ELISA performs equally well when using either plasma
or DBS, as confirmed by a high odds ratio value (Table 4).
Table 4. Sensitivity, specificity, PPV, NPV and odds ratio statistics comparisons of plasma and DBS
application using the CDC ELISA.
Standard ComparativeTest
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
Odds Ratio
(95% CI) P Value
CDC
Plasma 1:50
CDC
DBS1:50
97.7%
(88.0–99.9)
93.8%
(82.8–98.7)
93.5%
(82.7–97.7)
97.8%
(86.6–99.7)
645.0
(64.6–6442.6) <0.0001
3.3. Comparing Difference in Bm14 Antibody Units between Cellabs and CDC Assays
All unit concentrations, with the addition of one to include results of zero, were converted to
log values to approximate a normal distribution (Figure 1). Results were compared using geometric
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means. When analysing CELISA samples, the mean log value for plasma at 1.66 was significantly
lower than the mean log value of 2.10 for DBS (p < 0.0001) (Table 5). However, the mean log values
for CDC ELISA plasma and DBS samples at 2.03 and 2.07 respectively were not significantly different
(p = 0.34) (Table 5). The data suggests a rise in estimated concentration when using DBS in comparison
to plasma when using the CELISA, but not when using the CDC ELISA.
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using the CELISA and the CDC ELISA. 
4. Discussion 
The major finding of this study is the strong agreement between plasma and DBS samples, taken 
from the same individuals and stored identically, when applied to either the Cellabs produced 
CELISA or the CDC Bm14 ELISA. In the Cellabs CELISA protocol [13], the recommended dilution is 
set at 1:100. According to the instructions for the in-house CDC filariasis serology assay [14], the 
recommended dilution is set at 1:50 dilution using serum obtained from centrifuged blood. Despite 
these differences in dilution optimised for the two tests, the proportions of samples classified as 
Figure 1. Filariasis Bm14 ELISA log (antibody unit concentration +1) value comparisons between
plasma and DBS application of CELISA and CDC ELISA assays. Horizontal black lines refer to mean
concentration of each assay, with the segmented line referring to the cut-off value at log (125 units +1).
All concentrations above or equal to the defined cut-off are considered positive, while all readings
belo are considered negative.
Table 5. Geometric mean concentration values and t-test comparisons between plasma and DBS
application of CELISA and CDC ELISA assays.
Group 1 Group 2 t-Test
Test
Mean log
(Antibody
unit +1)
Geometric
mean Test
Mean log
(Antibody
unit +1)
Geometric
mean N
Mean
Difference SD p
CELISA
Plasma 1.66 45.00
CELISA
DBS 2.10 124.42 92 0.44 0.63 <0.0001
DC
Plasma 2.03 105.62 CDC DBS 2.07 115.51 92 0.04 0.39 0.34
. . l i fficie t l sis of 14 tibody oncentrations fro Plas a and Eluates from
Filter Paper
The log values of Bm14 unit concentrations, with the addition of one to include results of zero,
between plasma and DBS application were compared to determine correlation coefficients for both
CELISA and CDC ELISA assays. Strong correlations were found at 0.87 and 0.95 for CELISA (Figure 2A)
and the CDC ELISA (Figure 2B) respectively when comparing plasma and DBS samples (p < 0.0001).
This shows that quantitative values between plasma and DBS are strongly positively associated when
using the CELISA and the CDC ELISA.
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application. (A) CELISA at 1:100 dilution comparisons of plasma against DBS; (B) CDC ELISA at 1:50
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4. Discussion
The major finding of this study is the strong agreement between plasma and DBS samples, taken
from the same individuals and stored identically, when applied to either the Cellabs produced CELISA
or the CDC Bm14 ELISA. In the Cellabs CELISA protocol [13], the recommended dilution is set at 1:100.
According to the instructions for the in-house CDC filariasis serology assay [14], the recommended
dilution is set at 1:50 dilution using serum obtained from centrifuged blood. Despite these differences
in dilution optimised for the two tests, the proportions of samples classified as positive were not
significantly different, with performance (relative sensitivity, specificity and predictive values) being
very similar between all the tests.
High specificity and PPV values were found for comparisons of DBS against plasma using both
CELISA and CDC ELISA tests. According to Joseph and Melrose [8], results obtained using the
CELISA assay for BS yielded a specificity of 77%, with 16 samples testing positive by DBS but
negative by plasma, while PPV was found at 60%, suggesting that DBS sampling may result in false
positives at an approximate rate of 40%. However, this work was done with an earlier version of the
CELISA. Weil et al. [10] stated that blood samples with a known amount of antibody applied to DBS
are not significantly different to those from serum samples under controlled conditions when using
the CELISA. Our own results of 93.9% and 92.7% for specificity and PPV when comparing DBS and
plasma suggest that the CELISA assay has improved in these regards.
Analysis of quantitative data showed that correlation was high between plasma and DBS for
both the CELISA and CDC ELISA at >0.87. Although the mean antibody units were lower for DBS
than plasma in the CDC ELISA, the difference was not significant. The significantly higher sample
concentrations for DBS than plasma when using the CELISA suggests that this test gives higher
background for DBS. However, the categorical results suggest no significant difference in agreement
(classification of positives).If the amount of antibody present is important in future studies using DBS,
it may be necessary to keep this difference in mind.
The use of DBS could facilitate more effective sample collection in endemic countries, where
large-scale sampling must be undertaken with limited resources and also eliminates the risk of thawing
or leaking during shipping.
Ou analysis show d that both plasma a d filter paper demonstrate simil r results using both
the CELISA and CDC ELISA. High agreement wa also found wh n c mparing the CELISA using
plasma with CDC ELISA applications of either plasma or DBS. These results support the use of the
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Bm14 ELISA in assessing LF prevalence in the GPELF and can be used with either plasma or DBS on
filter paper.
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